News & Views

Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).

Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare Conference

Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2 clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).

Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at MSKCC

Telix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference.

Dr. Christian Behrenbruch, CEO of  Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which in 2018, hosted 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.

Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT on Tuesday 4th June 2019.